| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
185,611,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
6,246,627 |
Avg
Vol: |
2,834,746 |
| 52
Week Range: |
$23.99 - $23.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2013-12-19 |
4 |
AS |
$5.15 |
$18,528 |
D/D |
(3,600) |
135,399 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2013-12-19 |
4 |
AS |
$5.14 |
$26,214 |
D/D |
(5,100) |
91,157 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2013-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,750 |
80,649 |
|
- |
|
| Berstein David L |
Senior VP, Chief IP Officer |
• • – |
2013-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
225,898 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2013-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,500 |
390,069 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2013-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,500 |
247,984 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2013-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
138,999 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-12-18 |
4 |
D |
$4.98 |
$146,910 |
D/D |
(29,500) |
1,050,759 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
62,500 |
1,080,259 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2013-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,750 |
96,257 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• • – |
2013-11-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,250 |
102,532 |
|
- |
|
| Duvall Martin J |
SVP, Commercial Operations |
• • – |
2013-09-19 |
4 |
D |
$21.49 |
$234,628 |
D/D |
(10,918) |
23,821 |
|
- |
|
| Duvall Martin J |
SVP, Commercial Operations |
• • – |
2013-09-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
34,739 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2013-09-06 |
4 |
AS |
$22.00 |
$185,878 |
D/D |
(8,449) |
370,451 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-08-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
225,000 |
1,017,759 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-08-15 |
4 |
GA |
$0.00 |
$0 |
I/I |
225,000 |
245,251 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2013-08-15 |
4 |
D |
$18.11 |
$350,284 |
D/D |
(19,342) |
228,243 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2013-08-15 |
4 |
OE |
$3.90 |
$128,700 |
D/D |
33,000 |
247,585 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-08-14 |
4 |
AS |
$18.37 |
$57,999 |
I/I |
(3,157) |
0 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-08-14 |
4 |
AS |
$18.51 |
$1,164,335 |
D/D |
(62,902) |
1,242,759 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-08-13 |
4 |
AS |
$18.36 |
$49,570 |
I/I |
(2,700) |
3,157 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-08-13 |
4 |
AS |
$18.11 |
$905,555 |
D/D |
(50,000) |
1,305,661 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2013-07-18 |
4 |
AS |
$19.79 |
$126,642 |
D/D |
(6,400) |
83,507 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• • – |
2013-07-18 |
4 |
AS |
$19.79 |
$126,655 |
D/D |
(6,400) |
67,282 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2013-07-18 |
4 |
AS |
$19.79 |
$126,639 |
D/D |
(6,400) |
129,978 |
|
- |
|
703 Records found
|
|
Page 12 of 29 |
|
|
